Navigation Links
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
Date:12/10/2007

New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic

TSX Exchange Symbol: RVX

CALGARY, Dec. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

The Phase I clinical trial is taking place at a leading US contract research organization. The trial consist of three arms, an ascending single dose, a fed and fasted dose effect study, and a 7-day ascending multiple dose that will enroll a total of 70-80 healthy volunteers. The primary objective of the trial is to evaluate oral RVX-208 in healthy adult subjects for safety, tolerability, and pharmacokinetics. Results from this Phase 1a trial will be used for optimizing dosing for future trials including our Phase 1b trial.

Gregory S. Wagner, PhD, Senior Vice President, Preclinical Development of Resverlogix, stated that, "RVX-208 possesses a very favorable pharmacological and pharmaceutical profile. This compound is an excellent choice to be the first drug candidate from our preclinical pipeline, our research and development team has worked aggressively to rapidly advance it into clinical development."

"This field has been developing for 50 years. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in both animals and humans," stated Dr. Jan Johansson, MD, PhD. Senior Vice President of Clinical Affairs of Resverlogix. "We have identified a way to increase the endogenous production of ApoA-I via a small molecule drug. The initiation of this clinical trial is a milestone for the fi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Resverlogix is Presenting at IAS HDL Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... orders consist of three large odour control systems for waste ... "These orders are consistent with the market resurgence in ... , President and CEO. "After a difficult period of restraint ... beginning to see sales growth. Our lower cost structure, technology ...
(Date:9/1/2014)... , Sept. 1, 2014 Reportlinker.com ... available in its catalogue: India Solid ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html ... are the main governing bodies responsible for complete ... cities. On an average, around 135,000 MT solid ...
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3
... Vanderbilt University have developed a new technique that uses a ... multiple points simultaneously, a method that could help scientists study ... shape. UV lasers are a commonly-used tool for ... vaporizing one point at a time in a series of ...
... 2011 GNS Healthcare, Inc. (GNS) announced today ... Brigham and Women,s Hospital (BWH) , a teaching affiliate of ... adverse drug events and on hospital readmissions for patients admitted ... excited to announce this collaboration with Dr. Bates, Brigham and ...
... Florida-based SkinHealth Technology introduces a powerful, breakthrough formula ... botanical emollients -- with a proven skin protectant to ... ExtremeSkinCare Intense Treatment Balm helps reduce ... relieve inflamed and irritated skin without steroids . ...
Cached Biology Technology:GNS Healthcare, Inc Collaborates with Nationally Ranked Hospital to Predict Adverse Drug Events and Hospital Readmissions 2GNS Healthcare, Inc Collaborates with Nationally Ranked Hospital to Predict Adverse Drug Events and Hospital Readmissions 3New Dermatological Formula Targets Psoriasis, Eczema and Other Extreme Skin Conditions 2
(Date:9/1/2014)... adapted to a life without light. They emit echolocation sounds ... distance to obstacles or prey. In their brains, they have ... out by researchers at Technische Universitt Mnchen (TUM) has shown ... external factors. , Closer objects appear larger ... an object, the number of activated neurons in its brain ...
(Date:8/31/2014)... have discovered that ,good, cholesterol is turned ,bad, by ... MG, was found to damage ,good, HDL cholesterol, which ... , Low levels of HDL, High Density Lipoprotein, ... of MG being common in the elderly and those ... funding from the British Heart Foundation (BHF) and published ...
(Date:8/31/2014)... the highly infectious bacteria C. diff , that ... by a team at the University of Leicester. , ... that it is possible to identify the unique ,smell, ... rapid diagnosis of the condition., What is more, the ... different strains of the disease simply from their smell ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Sugar substance 'kills' good HDL cholesterol, new research finds 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... National Center for Research Resources (NCRR), part of ... will provide up to an estimated $122 million ... Development Award (IDeA) Networks of Biomedical Research Excellence ... development, coordination and sharing of research resources and ...
... membership agreement with BioMed Central to cover publication costs ... BioMed Central membership arrangement means that Pfizer will centrally ... funded by Pfizer when they submit a research article ... journals. By funding open access publication fees in this ...
... water resources in river basins were acknowledged and managed ... researchers from Stockholm Resilience Centre at Stockholm University, Stockholm ... The challenge of meeting future water needs under ... demands for water may be less bleak than widely ...
Cached Biology News:NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3Better water use could reduce future food crises 2Better water use could reduce future food crises 3
... The kit was tested on rat tissue extracts ... yeast ( S. cerevisae ) extract. It was ... tissues and cell lines. Application: A simple and ... fractions based on the detection of the inorganic ...
... CAST Equine EIA Principle: ... LTC4, LTD4 and LTE4 are ... by 5-lipoxygenase and glutathione-S-transferase. In ... termed "Slow Reacting Substances of ...
... stress is the condition in which a ... stimuli and the various antioxidants. Oxidative ... pathogenesis of several diseases, including artherosclerosis, chronic ... possesses several antioxidant systems that are very ...
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
Biology Products: